Food allergy is a potentially life-threatening condition, and its prevalence continues to
increase despite public health efforts. There are currently no known therapies that can
reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine
the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food
challenge in food-allergic adults.